ACS Medicinal Chemistry Letters
August 15, 2025
Robert B. Kargbo
Novel phenalkylamines and tryptamines such as psilocybin demonstrate promising nontraditional pharmacological profiles for treating psychiatric syndromes. Structural modifications yield functional selectivity at 5-HT receptors, mitigating hallucinogenic risk while preserving therapeutic efficacy. This study integrates receptor and behavioral data to support phenalkylamines and psilocybin as...
European Journal of Pharmacology
August 15, 2025
Niharika Singh, Puja Panwar Hazari, Parul Mittal et al.
16 citations
Globally, depression affects millions of people of all ages, making it one of the significant contributors to deteriorating quality of life by causing neurological impairments that eventually weaken cognition, learning, and memory. According to the monoamine hypothesis, depression is associated with decreased serotonin, dopamine, and norepinephrine levels in the central nervous system. Drugs...
psychopraxis neuropraxis
August 11, 2025
Arif de Mendelssohn, Henriette Löffler-stastka
Zusammenfassung Serotonin (5-HT) ist ein fundamentaler Neuromodulator, dessen komplexe Rolle in der Psychiatrie oft auf vereinfachte Modelle wie die „Chemische-Dysbalance-Hypothese“ reduziert wurde. Ein zeitgemäßes Verständnis von höherem heuristischen Wert erfordert demgegenüber die Integration verschiedener wissenschaftlicher Ansätze. Dieser Artikel synthetisiert die Theorien von Mark Solms...
International Journal of Molecular Sciences
August 4, 2025
Masahide Arinaga, Jun Yamada, Shoichiro Maeda et al.
2 citations
Cancer-related cognitive impairment (CRCI)-encompassing anxiety, depression, and memory deficits-significantly diminishes the quality of life in patients with cancer, yet remains underrecognized in clinical practice. In this study, we investigated the therapeutic potential of tabernanthalog (TBG), a non-hallucinogenic analog of psychedelic compounds, as a novel intervention for CRCI using a...
The International Journal of Neuropsychopharmacology
August 1, 2025
Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
Abstract Background Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), present a great promise for treating affective disorders. While the hallucinogenic activities of LSD are commonly attributed to stimulation of 5-HT2A receptors, their role in LSD’s antidepressant response is still in debate. Interestingly, LSD...
Pharmaceutical Science
August 1, 2025
Melissa Ortega
Ayahuasca is a traditional Amazonian brew composed primarily of Banisteriopsis caapi and Psychotria viridis, drawing increasing interest for its psychedelic effects and potential therapeutic applications. Its pharmacological action is based on the synergistic combination of β-carbolines (harmine, tetrahydroharmine, and harmaline), which act as reversible inhibitors of monoamine oxidase A...
The International Journal of Neuropsychopharmacology
August 1, 2025
B. D. Richardson, Marco Pileggi, Thomas Prudhomme et al.
Abstract Background Psychedelics hold potential as therapeutics in psychological disorders. Even if they primarily act on 5-HT2A receptors, their mechanisms and effects on the brain are not well understood. Simply activating 5-HT2A receptors does not induce psychedelic effects. For example, psilocybin and lisuride both bind to 5-HT2A receptors, but only psilocybin induces hallucinogenic...
Acta Neuropsychiatrica
July 25, 2025
Guillaume Thuery, Christopher Sheridan, Patricia Iusan et al.
4 citations
By synthesising findings from both clinical and preclinical research, this review aims to provide an understanding of the interplay between 5-HT2A receptor psychedelics and the immune system and considers how their immunomodulatory effects associate with neuronal and behavioural changes. A PubMed literature search covering the past 30 years was conducted using keywords such as "5-HT2A...
bioRxiv Preprint Server
July 23, 2025
Tomas Del Olmo, Mathilde Decourcelle, Martial Séveno et al.
preprint
The serotonin (5-HT)2A receptor is the primary target of numerous psychoactive drugs including serotonergic psychedelics, and mediates psychedelics-induced neuroplasticity, but the signaling mechanisms involved remain poorly characterized. Using quantitative phosphoproteomics, we show that the administration of the hallucinogenic 5-HT2A receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) to...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
July 16, 2025
Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.
12 citations
Recent clinical trials show that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), possess a great promise for treating affective disorders. Interestingly, LSD displays strong functional activity on 5-HT2B receptors and a modulatory role of the latter receptors in anxious and depressive-like behaviors has been reported. Using behavioral and in...